No Resistance to Tenofovir Disoproxil Fumarate Detected After up to 144 Weeks of Therapy in Patients Monoinfected With Chronic Hepatitis B Virus

被引:140
作者
Snow-Lampart, Andrea [1 ]
Chappell, Brandi [1 ]
Curtis, Maria [1 ]
Zhu, Yuao [1 ]
Myrick, Florence [1 ]
Schawalder, James [1 ]
Kitrinos, Kathryn [1 ]
Svarovskaia, Evguenia S. [1 ]
Miller, Michael D. [2 ]
Sorbel, Jeff [1 ]
Heathcote, Jenny [3 ]
Marcellin, Patrick [4 ]
Borroto-Esoda, Katyna [1 ]
机构
[1] Gilead Sci Inc, Durham, NC 27707 USA
[2] Gilead Sci Inc, Foster City, CA 94404 USA
[3] Univ Toronto, Toronto, ON, Canada
[4] Univ Paris, Hosp Beaujon, Clichy, France
关键词
IN-VITRO ACTIVITY; ADEFOVIR DIPIVOXIL; POLYMERASE MUTATIONS; LAMIVUDINE; REPLICATION;
D O I
10.1002/hep.24078
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue with potent activity against human immunodeficiency virus type 1 and hepatitis B virus (HBV). To date, no reports of HBV clinical resistance to TDF have been confirmed. In two phase 3 studies (GS-US-174-0102 and GS-US-174-0103), 375 hepatitis B e antigen-negative (HBeAg-) patients and 266 HBeAg+ patients with chronic hepatitis B (some nucleoside-naive and some lamivudine-experienced) were randomized 2:1 to receive TDF (n = 426) or adefovir dipivoxil (ADV; n = 215) for 48 weeks. After week 48, eligible patients received open-label TDF with no interruption. The studies are being continued through week 384/year 8; week 144 data are presented here. Per protocol, viremic patients (HBV DNA level >= 400 copies/mL or 69 IU/mL) had the option of adding emtricitabine (FTC) at or after week 72. Resistance analyses of HBV polymerase/reverse transcriptase (pol/RT) were based on population dideoxy sequencing. Phenotypic analyses were conducted in HepG2 cells with recombinant HBV derived from patient serum. Most patients maintained TDF monotherapy treatment across both studies (607/641, 95%). A resistance analysis of HBV pol/RT was performed at the baseline for all patients, for viremic patients at week 144 or at the last time when they were on TDF monotherapy (34 on TDF and 19 on ADV-TDF), and for patients who remained viremic after the addition of FTC (7/20 on TDF and 5/14 on ADV-TDF). No patient developed amino acid substitutions associated with resistance to TDF. Virological breakthrough on TDF monotherapy was infrequent over 144 weeks (13/426, 3%) and was attributed to documented nonadherence in most cases (11/13, 85%). Persistent viremia (>= 400 copies/mL) through week 144 was rare (5/641, 0.8%) and was not associated with virological resistance to TDF by population or clonal analyses. Conclusion: No nucleoside-naive or nucleoside-experienced patient developed HBV pol/RT mutations associated with TDF resistance after up to 144 weeks of exposure to TDF monotherapy. (HEPATOLOGY 2011;53:763-773)
引用
收藏
页码:763 / 773
页数:11
相关论文
共 27 条
  • [1] [Anonymous], 60 ANN M AM ASS STUD
  • [2] BARTHOLOMEUSZ A, 1997, INT ANTIVIRAL NEWS, V5, P123
  • [3] Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV)
    Berg, T.
    Moller, B.
    Trinh, H.
    Chan, S.
    Marcellin, P.
    Suarez, E.
    Snow-Lampart, A.
    Frederick, D.
    Oldach, D.
    Sorbel, J.
    Borroto-Esoda, K.
    Rousseau, E.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S34 - S34
  • [4] Berg T, 2009, 44 ANN M EUR ASS STU
  • [5] In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants
    Brunelle, M. N.
    Lucifora, J.
    Neyts, J.
    Villet, S.
    Holy, A.
    Trepo, C.
    Zoulim, F.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (06) : 2240 - 2243
  • [6] Four years of lamivudine treatment in Chinese patients with chronic hepatitis B
    Chang, TT
    Lai, CL
    Chien, RN
    Guan, R
    Lim, SG
    Lee, CM
    Ng, KY
    Nicholls, GJ
    Dent, JC
    Leung, NW
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (11) : 1276 - 1282
  • [7] Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus
    Delaney, WE
    Ray, AS
    Yang, HL
    Qi, XP
    Xiong, S
    Zhu, YA
    Miller, MD
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) : 2471 - 2477
  • [8] Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    Hadziyannis, Stephanos J.
    Tassopoulos, Nicolaos C.
    Heathcote, E. Jenny
    Chang, Ting-Tsung
    Kitis, George
    Rizzetto, Mario
    Marcellin, Patrick
    Lik, Seng Gee
    Goodman, Zachary
    Ma, Jia
    Brosgart, Carol L.
    Eorroto-Esoda, Katyna
    Arterburn, Sarah
    Chuck, Steven L.
    [J]. GASTROENTEROLOGY, 2006, 131 (06) : 1743 - 1751
  • [9] Harris J., 2008, 59 ANN M AM ASS STUD
  • [10] Heathcote E. J., 2009, 60 ANN M AM ASS STUD